Jefferies Financial Group Analysts Lower Earnings Estimates for LeMaitre Vascular, Inc. (NASDAQ:LMAT)

LeMaitre Vascular, Inc. (NASDAQ:LMATGet Rating) – Analysts at Jefferies Financial Group lowered their Q2 2022 earnings per share estimates for shares of LeMaitre Vascular in a research report issued to clients and investors on Thursday, April 28th. Jefferies Financial Group analyst Z. Weiner now forecasts that the medical instruments supplier will post earnings per share of $0.25 for the quarter, down from their previous estimate of $0.37. Jefferies Financial Group also issued estimates for LeMaitre Vascular’s Q3 2022 earnings at $0.32 EPS, Q4 2022 earnings at $0.32 EPS, FY2022 earnings at $1.16 EPS, FY2023 earnings at $1.49 EPS, FY2024 earnings at $1.67 EPS and FY2025 earnings at $1.87 EPS.

LMAT has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Thursday. Barrington Research cut their target price on shares of LeMaitre Vascular from $54.00 to $50.00 in a research note on Friday. Finally, StockNews.com began coverage on shares of LeMaitre Vascular in a report on Thursday, March 31st. They issued a “hold” rating for the company. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Buy” and an average target price of $57.00.

Shares of LMAT opened at $43.21 on Monday. The stock has a market capitalization of $948.55 million, a PE ratio of 34.57, a PEG ratio of 3.29 and a beta of 1.32. LeMaitre Vascular has a fifty-two week low of $39.48 and a fifty-two week high of $64.50. The business has a 50-day simple moving average of $45.73.

LeMaitre Vascular (NASDAQ:LMATGet Rating) last posted its quarterly earnings results on Thursday, April 28th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). The business had revenue of $39.56 million during the quarter, compared to the consensus estimate of $38.65 million. LeMaitre Vascular had a return on equity of 11.76% and a net margin of 17.09%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.28 earnings per share.

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 2nd. Shareholders of record on Tuesday, May 17th will be given a dividend of $0.125 per share. This represents a $0.50 annualized dividend and a yield of 1.16%. The ex-dividend date is Monday, May 16th. LeMaitre Vascular’s dividend payout ratio is presently 40.00%.

In other LeMaitre Vascular news, insider Trent G. Kamke sold 7,929 shares of the business’s stock in a transaction that occurred on Wednesday, March 2nd. The shares were sold at an average price of $48.22, for a total transaction of $382,336.38. The transaction was disclosed in a filing with the SEC, which is available at this link. 16.50% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Hong Kong Ltd acquired a new position in shares of LeMaitre Vascular in the 3rd quarter valued at $54,000. O Shaughnessy Asset Management LLC raised its position in LeMaitre Vascular by 827.8% during the third quarter. O Shaughnessy Asset Management LLC now owns 1,336 shares of the medical instruments supplier’s stock worth $71,000 after acquiring an additional 1,192 shares during the period. Hardy Reed LLC acquired a new position in LeMaitre Vascular during the first quarter worth $91,000. Quantinno Capital Management LP acquired a new position in LeMaitre Vascular during the third quarter worth $209,000. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in LeMaitre Vascular during the first quarter worth $247,000. Hedge funds and other institutional investors own 85.82% of the company’s stock.

About LeMaitre Vascular (Get Rating)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

Read More

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.